---
figid: PMC9371883__JO2022-8675096.002
pmcid: PMC9371883
image_filename: JO2022-8675096.002.jpg
figure_link: /pmc/articles/PMC9371883/figure/fig2/
number: Figure 2
figure_title: ''
caption: 'Linderalactone inhibits the proliferation of pancreatic cancer cells. (a,
  b) EdU staining assay detected the proliferation of BXPC-3 and CFPAC-1 cell lines
  under varying concentrations of LL treatment after 24 hours. (c, d) Quantiﬁcation
  of EdU stain: the percentage of EdU positive cells to the total number of cells.
  (e) Clone formation assay to detect the effect of LL on BXPC-3 and CFPAC-1 cell
  lines. (f) Quantification of clone formation. Scale bar = 200 μm. ∗p < 0.05; ∗∗p
  < 0.01.'
article_title: Linderalactone Suppresses Pancreatic Cancer Development In Vitro and
  In Vivo via Negatively Regulating PI3K/AKT Signaling Pathway.
citation: Dongchao Xu, et al. J Oncol. 2022;2022:8675096.
year: '2022'

doi: 10.1155/2022/8675096
journal_title: Journal of Oncology
journal_nlm_ta: J Oncol
publisher_name: Hindawi

keywords:
---
